 HAMILTON, Ontario and BOSTON , Aug. 31, 2021 PRNewswire -- Fusion Pharmaceuticals Inc. Nasdaq: FUSN, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Companys Board of Directors granted stock option awards to purchase an aggregate of 80,000 shares of its common stock to one employee outside Fusions 2020 Stock Option and Incentive Plan. The stock options were granted as an inducement material to the individual becoming an employee of Fusion in accordance with Nasdaq Listing Rule 5635c4. 